Using brain stimulation to improve memory in people with mild cognitive impairment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of transcranial alternating current stimulation (tACS) on enhancing working memory and cognitive functions in individuals diagnosed with Mild Cognitive Impairment (MCI). Participants aged 60 and older will receive non-invasive brain stimulation sessions lasting 1 to 1.5 hours, five days a week for two weeks at the Centre for Addiction and Mental Health. The study aims to assess the feasibility and preliminary effects of tACS on brain wave coupling and working memory performance. Clinical and cognitive assessments, along with bloodwork, will be conducted before and after the treatment period to evaluate outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 60 years or above,
2. Diagnosis of MCI due to AD using the core clinical criteria by the National Institute on Aging and Alzheimer's Association for MCI participants (NIA-AA) and ascertained by a study investigator. The following checklist will be used to ascertain the MCI diagnosis:

   1. Cognitive concern reflecting a change in cognition reported by patient or informant or clinician (i.e., historical or observed evidence of decline over time)
   2. Not demented ascertained using the study investigator opinion.
   3. No vascular, traumatic, or medical causes of cognitive decline ascertained using the study investigator opinion.
   4. Evidence of longitudinal decline in cognition, when feasible, and ascertained using the study investigator opinion.
3. Objective evidence of single or multi domain MCI, where single domain MCI refers to deficits using neuropsychology (NP) battery on only one of the cognitive domains (Speed of Processing; Working Memory; Executive Functioning; Verbal Memory; Visual Memory; Language) and multi domain MCI refers to deficits in more than one of these domains. To determine impairment in one or more cognitive domain, after the NP battery is administered and double scored, a consensus meeting will be held with the Research Analyst/Fellow, the study Principal Investigator and the study Neuropsychologist during which eligibility will be discussed. The meeting attendees will take into consideration the participant's education, parental education, pre-morbid IQ, physician's assessment and NP scores to determine if the participant has impairment in one or more cognitive domain.
4. Willingness to provide informed consent,
5. Ability to read and communicate in English (with corrected vision and hearing, if needed)

Exclusion Criteria:

1. Current use of an acetylcholine esterase inhibitor or memantine ascertained via participant's report, Medication List, or Electronic Medical Record (EMR).
2. Major Depressive Disorder with active symptoms in the last 3 months ascertained using the Mini International Neuropsychiatric Interview (MINI), or Structured Clinical Interview for DSM-5 (SCID), or EMR.
3. A lifetime diagnosis of bipolar disorder; intellectual disability; or a psychotic disorder ascertained using the MINI or SCID, or EMR.
4. Substance use disorder active in the last 3 months ascertained using the MINI or SCID, or EMR.
5. Any other DSM-5 diagnosis ascertained using the MINI or SCID, or EMR, that may be associated with prefrontal cortical dysfunction as ascertained using a study investigator opinion.
6. Current anticonvulsant use due to its impact on brain stimulation induced activity and ascertained using a Medication List or EMR. An exception will be made if they are taking gabapentin or pregabalin AND if the dose had been stable for at least 4 weeks prior to study entry AND if prescribed for chronic pain.
7. Current benzodiazepine use of more than what is equivalent to lorazepam 2 mg/day as ascertained using a Medication List. This is due to their known pro-GABAergic activity and the suppressive effect of GABAergic agents on cortical plasticity
8. Any contraindication to MRI or contraindication to tACS (e.g., cardiac pacemaker, acoustic device, history of seizures) ascertained using the tACS Safety Screen (tSS)

Where it's running

• Centre for Addiction and Mental Health
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Sanjeev Kumar, MD — Centre for Addiction and Mental Health
• Study coordinator: Sanjeev Kumar, MD
• Email: Sanjeev.Kumar@camh.ca
• Phone: 416-535-8501

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rural Veterans and Care Partners Walking Program

  A virtual walking program is tested to see if it can help Veterans with mild cognitive impairment and their care partners in rural areas walk more each day.

  Recruiting Creighton University · Omaha, Nebraska · NCT07914218

• China HEAD: a large community study on healthy aging and dementia

  This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.

  Recruiting at 30 sites Fudan University · Beijing and 29 other locations · NCT07912710

• Aging Brain Health Initiative in Fujian

  This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.

  Recruiting at 4 sites Fujian Medical University Union Hospital · Fushun, Fujian and 3 other locations · NCT07891429

• See if multimodal biomarkers can map changes from mild cognitive impairment to dementia

  This observational study tests whether clinical, blood, and brain-imaging markers can tell apart stages of cognitive decline and predict progression from mild cognitive impairment to dementia in about 600 people.

  Recruiting Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT07876570

• LIFU to Help Sleep and Amyloid Reduction in Older Adults with Cognitive Impairment

  A wearable ultrasound device (ATTN201) is being tested to see if it’s safe and easy to use for people 65 and older with mild cognitive impairment and amyloid buildup.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07866768

• Digital STEADI: A home-based digital fall prevention program for older adults

  A home-based digital program using AI-driven conversational agents tests if a guided fall-prevention exercise plan can reduce fall risk for older adults with mild cognitive impairment living independently.

  Recruiting Phase 1/2 Friendi.fi Corporation · Atlanta, Georgia · NCT07852650

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.